Journal: Diagnostics

Article Title: CD5L as an Extracellular Vesicle-Derived Biomarker for Liquid Biopsy of Lung Cancer

doi: 10.3390/diagnostics11040620

Figure Lengend Snippet: Properties of top 10 candidate lung cancer biomarkers selected from the list of differentially upregulated proteins obtained using matrix-assisted laser desorption ionization–time-of-flight mass spectrometry (MALDI–TOF MS).

Article Snippet: The following primary antibodies were used: CD5L (LSBio, Seattle, WA, USA), RBP4 (GeneTex, Irvine, CA, USA), CLEC3B, ITIH4, SERFINF1, DBP, and β-actin (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), SAA4, SAA1, and SAA1 C20ORF3 (Abcam, Cambridge, MA, USA), and SERFINC1 and FCN3 (MyBioSource, San Diego, CA, USA).

Techniques: Mass Spectrometry, Binding Assay

Journal: Diagnostics

Article Title: CD5L as an Extracellular Vesicle-Derived Biomarker for Liquid Biopsy of Lung Cancer

doi: 10.3390/diagnostics11040620

Figure Lengend Snippet: Network analysis performed using ingenuity pathway analysis (IPA). ( A ) Network 1 including nine of the previously identified differentially expressed proteins. ( B ) Network 2 with CD5L as the hub protein.

Article Snippet: The following primary antibodies were used: CD5L (LSBio, Seattle, WA, USA), RBP4 (GeneTex, Irvine, CA, USA), CLEC3B, ITIH4, SERFINF1, DBP, and β-actin (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), SAA4, SAA1, and SAA1 C20ORF3 (Abcam, Cambridge, MA, USA), and SERFINC1 and FCN3 (MyBioSource, San Diego, CA, USA).

Techniques:

Journal: Diagnostics

Article Title: CD5L as an Extracellular Vesicle-Derived Biomarker for Liquid Biopsy of Lung Cancer

doi: 10.3390/diagnostics11040620

Figure Lengend Snippet: Transfection of siCD5L into BEAS-2B and A549 cells. ( A ) CD5L mRNA expression analyzed by RT-qPCR. ( B ) Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression analyzed by RT-qPCR. ( C ) CD5L protein expression in parent cells analyzed by Western blotting. ( D ) CD5L protein expression in EVs analyzed by Western blotting. ( E ) Quantitative analysis of CD5L by Western blotting in cells. ( F ) Quantitative analysis of CD5L by Western blotting in EVs. No siRNA, control group without transfection of siRNA; Control siRNA, cells transfected with control siRNA as negative control; GAPDH siRNA, cells transfected with GAPDH siRNA as positive control; CD5L siRNA, cells transfected with CD5L siRNA. * p < 0.05.

Article Snippet: The following primary antibodies were used: CD5L (LSBio, Seattle, WA, USA), RBP4 (GeneTex, Irvine, CA, USA), CLEC3B, ITIH4, SERFINF1, DBP, and β-actin (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), SAA4, SAA1, and SAA1 C20ORF3 (Abcam, Cambridge, MA, USA), and SERFINC1 and FCN3 (MyBioSource, San Diego, CA, USA).

Techniques: Transfection, Expressing, Quantitative RT-PCR, Western Blot, Negative Control, Positive Control